Abstract:
Objective To analyze the efficacy and the adverse reactions of conventional treatment-failed advanced refractory ovarian cancer cases after treatment with apatinib.
Methods Six patients enrolled in the Second Hospital of Tianjin Medical University from June 2015 to October 2015 received treatment with apatinib. Treatment efficacy was evaluated by imaging and analysis of tumor markers, including CA125, CEA, and NSE.
Results The age range of the six patients was 48-71 years (median: 55 years). Their histopathological subtypes included poorly differentiated serous cystadenocarcinoma (4/6), borderline papillary adenoma (1/6), and clear cell carcinoma (1/6). Clinical evaluation of patients revealed no cases with complete remission, two cases with partial response, one case with stable disease, and three cases with progressive disease. The objective response rate was 33% (2/6) and the disease control rate was 50% (3/6). In all patients, the main side effects were hypertension and hand-foot syndrome, which were controlled.
Conclusions The treatment of conventional treatment-failed advanced refractory ovarian cancer with apatinib has better exact effects, and medical toxicity can be controlled. In the future, to seek more effective treatment strategies, the mechanism of apatinib in the treatment of advanced ovarian cancer should be further explored.
下载: